secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001628280-25-050796
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash
--------------------------------------------------------------------------------

- Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.
- Net loss $41.0M ($0.30 per share) vs $44.0M ($0.42) in Q3 2024; adjusted net loss $25.5M ($0.19).
- Completed $60M PIPE financing with $57.6M net proceeds; pro forma cash $292.3M to support ZYNLONTA expansion.
- LOTIS-7 updated data by end of 2025; LOTIS-5 topline data expected 1H 2026; FL IIT shows ORR 98.2%, CR 83.6%.
- IND-enabling for PSMA-targeting ADC to be completed by end of 2025; restructuring costs $13.5M YTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828025050796/0001628280-25-050796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828025050796/adc-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer